PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12339172

Gonococcal pilus vaccine development project by Bactex.

View original source ↗Export metadata ↓

Abstract

Gonococcal pilus vaccine development project by Bactex includes a recently completed clinical trial involving approximately 3500 US army volunteers in Korea. Results of the double-blind, placebo controlled study, conducted during the 1st 8 weeks of 1983, are currently being analyzed. The findings will be confirmed by further testing and if the vaccine proves effective, Bactex plans to apply for a biological license. Bactex was founded in 1974 with the assistance of loans from the Center for Entrepreneurial Development at Carnegie Mellon University. The center at Carnegie, set up and funded by the National Science Foundation, serves to stimulate the transfer of technology from the academic community to industry. Similar centers have been established at MIT and the University of Washington, Bactex President and University of Pittsburgh microbiologist Charles Brinton told "The Blue Sheet" the company is developing additional human vaccines based on pilus technology. He noted that the firm also has a joint agreement with Schering's Animal Health Division for the production of animal vaccines. Under this agreement, Bactex developed a vaccine for neonatal diarrhea in piglets, which Schering began marketing about a month ago. In addition to the study in Korea, Brinton has tested the gonorrhea vaccine in approximately 230 volunteers at the University of Pittsburgh. The Korean trial was partially funded by the US Army Medical Research and Development Command.

Explore related subjects

AsiaDelivery of Health CareDeveloping CountriesDiseaseDouble-Blind MethodAsia, EasternHealthHealth ServicesImmunizationInfectionsKoreaPrimary Health CareResearchSexually Transmitted DiseasesVaccinationDelivery Of Health CareDiseasesDouble-blind StudiesEastern AsiaKorea, Republic OfReproductive Tract InfectionsResearch MethodologyStudiesJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

1983-05-04. Gonococcal pilus vaccine development project by Bactex.. https://pubmed.ncbi.nlm.nih.gov/12339172/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Reassortment of Highly Pathogenic Avian Influenza as a Driver for Zoonotic Spillover, Asia.

Highly pathogenic avian influenza H5Nx viruses remain a major zoonotic threat, yet global attention has focused largely on clade 2.3.4.4b, potentially overlooking major changes within long-endemic H5N1 lineages in Asia. Recent reports from South and Southeast Asia describe the emergence of reassortant clade 2.3.2.1 viruses alongside renewed human infections after apparent prolonged epidemiologic stability. Collectively, those events suggest a regional pattern rather than isolated anomalies. In this article, we argue that reassortment, rather than point mutation alone, might be an underrecognized driver of zoonotic risk in endemic H5N1 lineages and is reshaping those lineages. We examine why such events might be underrecognized in settings with entrenched poultry influenza, identify limitations of current surveillance systems, and call for integrated, real-time approaches linking genomic detection with phenotypic assessment across animal and human health sectors to enable timely risk assessment and coordinated public health action.

Asia↗
PubMed2026

Financing and health system capacity for precision medicine in Asia: a six country landscape analysis.

BACKGROUND: Precision medicine (PM) adoption is accelerating across Asia, but implementation remains uneven due to differences in financing, infrastructure, governance, and health-system readiness. OBJECTIVES: To examine how six Asian countries (Singapore, South Korea, China, Malaysia, Thailand, and Indonesia) adopt, finance, and integrate PM technologies, and identify common implementation patterns and challenges. METHODS: A landscape review of peer-reviewed literature, government publications, and HTA reports (2010-2026) was conducted, supplemented by stakeholder consultations. PM applications were grouped into public health screening (hereditary breast and ovarian cancer [HBOC] and familial hypercholesterolemia [FH] cascade testing), next-generation sequencing (NGS) applications (rare diseases, oncology, pharmacogenomics), and AI-enabled PM. Evidence was synthesized across access, awareness, reimbursement, and implementation. RESULTS: Public health genomic screening demonstrated the highest implementation readiness, followed by precision oncology, while rare disease diagnostics remained infrastructure-dependent and pharmacogenomics and AI-enabled PM platforms were at earlier stages. Four readiness profiles emerged: highly aligned systems; reimbursement-constrained systems with strong governance and infrastructure; systems strengthening governance, public financing and infrastructure; and strategy-led systems expanding implementation through pilot programs and referral centers. CONCLUSIONS: PM implementation across Asia remains heterogeneous. The identified readiness profiles highlight governance, financing, and infrastructure priorities for sustainable and equitable PM diffusion.

Asia↗
PubMed2026

Double heterozygous germline pathogenic variants in patients referred to a tertiary cancer genetics clinic in Singapore.

BACKGROUND: The increasing use of multigene panel testing has led to a rise in the identification of double heterozygous (DH) pathogenic variants in cancer patients, although their frequency and clinical relevance remain poorly characterised, particularly in Asian populations. METHODS: We conducted a retrospective review of 5,178 patients referred to a tertiary cancer genetics clinic in Singapore. DH pathogenic variants were defined as the presence of two or more distinct pathogenic or likely pathogenic germline variants identified by multigene panel testing. Clinical, pathological, and family history data were reviewed and analysed using appropriate non-parametric and exact statistical methods. RESULTS: Among 2,802 index patients with available genetic test results, 593 (21.2%) carried at least one pathogenic/likely pathogenic variant. DH pathogenic variants were identified in 21 individuals (0.75%), of which 9 were patients with breast cancer, 10 with non-breast malignancies, and 2 were cancer-free. The frequency of multiple primary cancers was 26.3% in DH variant carriers, 23.3% in single variant carriers, and 16.5% in those with no pathogenic variants. The median ages of first cancer diagnosis were 47, 44, and 48 years. Several DH combinations involved moderate- or low-penetrance genes, and some clinically unsuspected variants were detected only through broad multigene testing. CONCLUSION: DH pathogenic variants represent a rare subgroup that is increasingly detected through multigene panel testing. Their phenotypic expression is variable, and the influence of additional pathogenic variants remains uncertain. Our findings emphasise the need for tailored genetic evaluation and further research to guide evidence-based management for this complex patient population.

Asia↗